PDCD1LG2 and neoplasm: By understanding the intricate relationship between immune checkpoint molecules like PD-L1 and PD-L2 and the histological subtypes and grades of the disease, clinicians can tailor treatment regimens to target specific molecular pathways associated with tumour progression and immune evasion.